arrow
C

Cyril Quivoron

translational research hematological laboratory, ammica, inserm us23/cnrs ums3655, gustave roussy cancer campus, villejuif, france
H指数:16
被引数:3,274

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Notch pathway inhibition with crenigacestat (LY3039478) in a phase I first-in-human clinical trial for patients with relapsed or refractory non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia

使用crenigacestat(LY3039478)抑制Notch通路在复发或难治性非霍奇金淋巴瘤和B细胞慢性淋巴细胞白血病患者中的I期首次人体临床试验

2025-07-310
OA
Sequence analyses of relapsed or refractory diffuse large B-cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH-EP1 study
2023-01-181
OAAI
Molecular Landscape of Therapy-related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers
2021-09-0113
OAAI
Innovative therapies based on molecular orientation in patients with relapse and refractory diffuse large B-cell lymphoma: Results of LNH-EP1 study
2021-07-102
OAAI
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib
2018-07-16146
OAAI
B-cell tumor development in Tet2-deficient mice
2018-03-2643
OAAI
Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations
LEUKEMIA
IF13.4
2018-02-2618
PREAI
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
2018-01-19375
OAAI
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations
2017-04-30382
OAAI
IDH mutations and tumorigenicity
2013-11-011
PRE